drugset

drugset / Trial / NCT06481956

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

NCT06481956 ↗

Phase 2 Enrolling by invitation 40 enrolled Zheng Yabing

NaSingle-groupOpen-labelTreatment

Summary

To explore the efficacy and safety of T-DM1 combined with CDK4/6 inhibitor Ribociclib in the treatment of HER2-positive advanced breast cancer.

Timeline

Start: 2023-10-25
Primary completion: 2027-01-10
Completion: 2027-10-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ribociclib	Small molecule	400 mg	Oral

Indications